MeiraGTx Holdings plc Ordinary Shares (MGTX)
MeiraGTx Holdings plc is a clinical-stage gene therapy company focused on developing treatments for rare and serious diseases. Based in the UK, the company specializes in creating advanced gene therapy products using proprietary platforms to deliver potentially curative therapies for conditions such as neurological, ophthalmic, and infectious diseases.
Company News
MeiraGTx reported Q2 2025 results with significant revenue growth but missed analyst estimates. The company advanced several gene therapy programs, secured key partnerships, and maintained strong manufacturing capabilities despite ongoing financial challenges.
A comprehensive analysis reveals over 70 companies developing AAV gene therapies for hereditary retinal diseases, offering potential transformative treatments for vision restoration through advanced gene therapy techniques.
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of 12.27% and 93.94%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings. KMX reported a third-quarter sales decline of 5.5% year-on-year to $6.15 billion, missing the analyst consensus estimate of $6.33 billion. EPS of $0.52 beat the consensus estimate of $0.44. CarMax shares climbed 7.7% to $...
Sanofi may use company's gene regulation technology in immunology, metabolic disease and other conditions